Radiolabeled somatostatin analogs in prostate cancer

Mathew L. Thakur; H. Kolan; J. Li; R. Wiaderkiewicz; V. R. Pallela; R. Duggaraju; A. V. Schally

doi:10.1016/S0969-8051(96)00180-1

Radiolabeled somatostatin analogs in prostate cancer

Mathew L. Thakur, H. Kolan, J. Li, R. Wiaderkiewicz, V. R. Pallela, R. Duggaraju, A. V. Schally

Research output: Contribution to journal › Article

51 Scopus citations

Abstract

Vapreotide (RC-160), a somatostatin analog, was labeled with ^99mTc by a direct method and also by using CPTA [1,4,8,11-tetraazacyclotetradecane] as a bifunctional chelating agent. The labeled compounds were evaluated in nude mice bearing experimental human prostate cancers. In these studies, ¹¹¹InDTPA-D-Phe-Octreotide (¹¹¹In-DTPA-octreotide) served as a standard and ^99mTc-oxytocin as a receptor-non-specific control. ^99mTc-octreotide was also used. The 24 h tumor uptake of ^99mTc-RC-160 was nearly 400% higher, (p < 0.05), than that of ¹¹¹In-DTPA-octreotide and diminished upon receptor blocking. In all tissues except the kidneys, the uptake of ^99mTc-RC-160 was also higher than that of ¹¹¹In-DTPA-octreotide. The uptake of ^99mTc-RC-160 was influenced by the amount of peptide injected and the best tumor/muscle and tumor/blood ratios were obtained when only one μg of the peptide (200 Ci/mmol) was administered.

Original language	English (US)
Pages (from-to)	105-113
Number of pages	9
Journal	Nuclear Medicine and Biology
Volume	24
Issue number	1
DOIs	https://doi.org/10.1016/S0969-8051(96)00180-1
State	Published - Jan 1 1997
Externally published	Yes

Keywords

Tc labeled octreotide
Tc labeled RC-160
imaging prostate cancer
radiolabeled somatostatin analogs
receptor specific peptides in prostate cancer

ASJC Scopus subject areas

Cancer Research
Molecular Medicine
Radiology Nuclear Medicine and imaging

Access to Document

10.1016/S0969-8051(96)00180-1

Fingerprint Dive into the research topics of 'Radiolabeled somatostatin analogs in prostate cancer'. Together they form a unique fingerprint.

Cite this

Thakur, M. L., Kolan, H., Li, J., Wiaderkiewicz, R., Pallela, V. R., Duggaraju, R., & Schally, A. V. (1997). Radiolabeled somatostatin analogs in prostate cancer. Nuclear Medicine and Biology, 24(1), 105-113. https://doi.org/10.1016/S0969-8051(96)00180-1

@article{a24d6aa7486449cd8c9328a1b86dd8bf,

title = "Radiolabeled somatostatin analogs in prostate cancer",

abstract = "Vapreotide (RC-160), a somatostatin analog, was labeled with 99mTc by a direct method and also by using CPTA [1,4,8,11-tetraazacyclotetradecane] as a bifunctional chelating agent. The labeled compounds were evaluated in nude mice bearing experimental human prostate cancers. In these studies, 111InDTPA-D-Phe-Octreotide (111In-DTPA-octreotide) served as a standard and 99mTc-oxytocin as a receptor-non-specific control. 99mTc-octreotide was also used. The 24 h tumor uptake of 99mTc-RC-160 was nearly 400% higher, (p < 0.05), than that of 111In-DTPA-octreotide and diminished upon receptor blocking. In all tissues except the kidneys, the uptake of 99mTc-RC-160 was also higher than that of 111In-DTPA-octreotide. The uptake of 99mTc-RC-160 was influenced by the amount of peptide injected and the best tumor/muscle and tumor/blood ratios were obtained when only one μg of the peptide (200 Ci/mmol) was administered.",

keywords = "Tc labeled octreotide, Tc labeled RC-160, imaging prostate cancer, radiolabeled somatostatin analogs, receptor specific peptides in prostate cancer",

author = "Thakur, {Mathew L.} and H. Kolan and J. Li and R. Wiaderkiewicz and Pallela, {V. R.} and R. Duggaraju and Schally, {A. V.}",

year = "1997",

month = jan,

day = "1",

doi = "10.1016/S0969-8051(96)00180-1",

language = "English (US)",

volume = "24",

pages = "105--113",

journal = "Nuclear Medicine and Biology",

issn = "0969-8051",

publisher = "Elsevier Inc.",

number = "1",

}

TY - JOUR

T1 - Radiolabeled somatostatin analogs in prostate cancer

AU - Thakur, Mathew L.

AU - Kolan, H.

AU - Li, J.

AU - Wiaderkiewicz, R.

AU - Pallela, V. R.

AU - Duggaraju, R.

AU - Schally, A. V.

PY - 1997/1/1

Y1 - 1997/1/1

N2 - Vapreotide (RC-160), a somatostatin analog, was labeled with 99mTc by a direct method and also by using CPTA [1,4,8,11-tetraazacyclotetradecane] as a bifunctional chelating agent. The labeled compounds were evaluated in nude mice bearing experimental human prostate cancers. In these studies, 111InDTPA-D-Phe-Octreotide (111In-DTPA-octreotide) served as a standard and 99mTc-oxytocin as a receptor-non-specific control. 99mTc-octreotide was also used. The 24 h tumor uptake of 99mTc-RC-160 was nearly 400% higher, (p < 0.05), than that of 111In-DTPA-octreotide and diminished upon receptor blocking. In all tissues except the kidneys, the uptake of 99mTc-RC-160 was also higher than that of 111In-DTPA-octreotide. The uptake of 99mTc-RC-160 was influenced by the amount of peptide injected and the best tumor/muscle and tumor/blood ratios were obtained when only one μg of the peptide (200 Ci/mmol) was administered.

AB - Vapreotide (RC-160), a somatostatin analog, was labeled with 99mTc by a direct method and also by using CPTA [1,4,8,11-tetraazacyclotetradecane] as a bifunctional chelating agent. The labeled compounds were evaluated in nude mice bearing experimental human prostate cancers. In these studies, 111InDTPA-D-Phe-Octreotide (111In-DTPA-octreotide) served as a standard and 99mTc-oxytocin as a receptor-non-specific control. 99mTc-octreotide was also used. The 24 h tumor uptake of 99mTc-RC-160 was nearly 400% higher, (p < 0.05), than that of 111In-DTPA-octreotide and diminished upon receptor blocking. In all tissues except the kidneys, the uptake of 99mTc-RC-160 was also higher than that of 111In-DTPA-octreotide. The uptake of 99mTc-RC-160 was influenced by the amount of peptide injected and the best tumor/muscle and tumor/blood ratios were obtained when only one μg of the peptide (200 Ci/mmol) was administered.

KW - Tc labeled octreotide

KW - Tc labeled RC-160

KW - imaging prostate cancer

KW - radiolabeled somatostatin analogs

KW - receptor specific peptides in prostate cancer

UR - http://www.scopus.com/inward/record.url?scp=0030975591&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0030975591&partnerID=8YFLogxK

U2 - 10.1016/S0969-8051(96)00180-1

DO - 10.1016/S0969-8051(96)00180-1

M3 - Article

C2 - 9080482

AN - SCOPUS:0030975591

VL - 24

SP - 105

EP - 113

JO - Nuclear Medicine and Biology

JF - Nuclear Medicine and Biology

SN - 0969-8051

IS - 1

ER -